- We will send in 10–14 business days.
/images/books/10364330/9781493910120.jpg)
- Publisher: Humana
- Year: 2014
- Pages: 259
- ISBN-10: 1493910124
- ISBN-13: 9781493910120
- Format: 15.6 x 23.4 x 1.6 cm, hardcover
- Language: English
- SAVE -10% with code: EXTRA
Cholestatic Liver Disease (e-book) (used book) | bookbook.eu
Reviews
Description
Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease.
Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 16d.13:41:28
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Publisher: Humana
- Year: 2014
- Pages: 259
- ISBN-10: 1493910124
- ISBN-13: 9781493910120
- Format: 15.6 x 23.4 x 1.6 cm, hardcover
- Language: English English
Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease.
Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.
Reviews